Ultime prove

EudraCT Number: 2006-004076-13

Sponsor Protocol Number: 5

Start Date: 2006-11-28

Sponsor Name: Huvud- hals- lung- och hudcancer, Tema Cancer Karolinska Universitetssjukhuset

Full Title: Secar I Part I: A study of MTD of Sodium selenite in patients with advanced carcinoma. A phase I study. Amendment 5: continuous treatment

Medical condition: Patients with stage III or IV cancer in whom first and second line treatment have been given but who have tumours that are still progressing, giving symptomes. The patients must be in a fairly good...

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Restarted)

Trial results: (No results available)

EudraCT Number: 2006-005239-32

Sponsor Protocol Number: PDE5

Start Date: 2006-11-28

Sponsor Name: Medical Sciences, Akademiska sjukhuset

Full Title: Fosfodiesterashämmares akuta hemodynamiska effekter vid pulmonell hypertension och utvärdering av kväveoxid mätningar som icke-invasiv diagnostisk metod

Medical condition:  Pulmonell hypertension med kvarstående förhöjt medeltryck i arteria pulmonalis överstigande 25 mmHg i vila eller >30 mmHg under ansträngning vid hjärtkateterisering definierad av National Institu...

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2007-006754-26

Sponsor Protocol Number: PLA/01/06

Start Date: 2006-11-28

Sponsor Name: MASTELLI SRL

Full Title: DIABETIC FOOT ULCERS AND POLYDEOXYRIBONUCLEOTIDE (PLACENTEX INTEGRO MASTELLI) AS A TREATMENT FOR WOUND HEALING

Medical condition: Diabetic foot ulcer

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10056340	Diabetic ulcer	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed) SI (Completed)

Trial results: (No results available)

EudraCT Number: 2006-003876-37

Sponsor Protocol Number: CS866CM-B-E301

Start Date: 2006-11-28

Sponsor Name: DAIICHI SANKYO EUROPE GmbH

Full Title: Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy

Medical condition: Essential hypertension

Disease:	Version	SOC Term	Classification Code	Term	Level
	8.1		10015488	Essential hypertension	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) CZ (Completed) FR (Ongoing) ES (Completed)

Trial results: View results

EudraCT Number: 2006-002565-39

Sponsor Protocol Number: 2006015

Start Date: 2006-11-27

Sponsor Name: South Tees Acute Hospitals NHS Trust

Full Title: Effects of the Modification of the Daily Flow Rate with a Constant Daily Dose on Patient's Reported Analgesia in Intathecal Therapy

Medical condition: Chronic Pain.

Disease:	Version	SOC Term	Classification Code	Term	Level
	8.1		10049475	Chronic pain	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2006-004979-35

Sponsor Protocol Number: 05-FOR-01 SE

Start Date: 2006-11-27

Sponsor Name: Andi - Ventis

Full Title: A RANDOMISED, FOUR WAY CROSS-OVER STUDY TO ASSESS BRONCHODILATION, SAFETY AND TOLERABILITY OF NEW GENERIC DRY POWDER FORMOTEROL FORMULATIONS GIVEN AS CUMULATIVE DOSES FROM A NOVEL DRY POWDER INHALE...

Medical condition: reversible mild asthma

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults

Gender: Male, Female

Trial protocol: HU (Completed)

Trial results: (No results available)

EudraCT Number: 2006-003870-88

Sponsor Protocol Number: RPCE06G2013

Start Date: 2006-11-27

Sponsor Name: UCB Pharma S.A.

Full Title: A Phase IIIb, multi-center, double-blind, placebo-controlled, randomized trial to examine the corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease...

Medical condition: In the present study, the corticosteroid-sparing effect of certolizumab pegol will be assessed in patients with moderate to severe Crohn’s disease who have received initial acute corticosteroid the...

Disease:	Version	SOC Term	Classification Code	Term	Level
	8.1		10011401	Crohn's disease	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2006-003699-36

Sponsor Protocol Number: 20050154

Start Date: 2006-11-27

Sponsor Name: Amgen Inc.

Full Title: A Phase 2, Randomized, Double Blind, Placebo- Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Chemotherapy- Induced Thrombocytopenia in Su...

Medical condition: Secondary prophylaxis for the treatment of chemotherapy induced thrombocytopenia (CIT) in subjects with Non-Small Cell Lung Cancer (NSCLC) receiving myelosuppressive chemotherapy.

Disease:	Version	SOC Term	Classification Code	Term	Level
	8.1		10023780	Large cell lung cancer stage IV	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IE (Completed) PT (Completed) AT (Prematurely Ended) HU (Completed) DE (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2006-000813-39

Sponsor Protocol Number: H7T-MC-TABL

Start Date: 2006-11-27

Sponsor Name: Eli Lilly and Company

Full Title: Prasugrel in comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation (PRINCIPLE) - TIMI 44

Medical condition: subjects undergoing elective cardiac catheterization with planned percutaneous coronary intervention (PCI) with coronary stenting.

Disease:	Version	SOC Term	Classification Code	Term	Level
	8.1		10023031	Ischemia coronary artery origin	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Ongoing) DE (Completed)

Trial results: View results

EudraCT Number: 2006-002216-10

Sponsor Protocol Number: 2006012

Start Date: 2006-11-27

Sponsor Name: Procter & Gamble Pharmaceuticals

Full Title: A Multicenter, Double-blind, Randomized, Parallel, Placebo-controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of 2 Oral Doses, 25 mg Twice Daily and 100 mg Twice Daily, of PG 7...

Medical condition: Rheumatoid Arthritis

Disease:	Version	SOC Term	Classification Code	Term	Level
	8.1		10039073	Rheumatoid arthritis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Completed) HU (Completed) NL (Completed) GB (Completed)

Trial results: (No results available)

Ultime prove

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici